Compare CBZ & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | IMNM |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 1996 | 2020 |
| Metric | CBZ | IMNM |
|---|---|---|
| Price | $54.50 | $24.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $41.33 | $32.80 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | 51.40 |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $922,003,000.00 | $6,941,000.00 |
| Revenue This Year | $3.92 | N/A |
| Revenue Next Year | $4.12 | $1,127.34 |
| P/E Ratio | $19.25 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $24.29 | $8.67 |
| 52 Week High | $67.24 | $27.65 |
| Indicator | CBZ | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 81.19 | 72.37 |
| Support Level | $50.29 | $19.28 |
| Resistance Level | $55.39 | $27.14 |
| Average True Range (ATR) | 1.02 | 1.06 |
| MACD | 0.80 | 0.25 |
| Stochastic Oscillator | 93.34 | 87.53 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.